Ishiura Y, Fujimura M, Ohkura N, et al. - Some guidelines recommend using triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β2 agonists for treating asthma-chronic obstructive pulmonary disease overlap (ACO), which is characterized by airway limitation and is an important condition with high incidence and mortality. Researchers here performed a 12-week, randomized, open-label cross-over pilot study in 19 patients (19 males and no females; mean age: 70.7 ± 7.6 years) with ACO to examine the effect of triple therapy with glycopyrrolate (GLY) 50 μg/day on budesonide/formoterol fumarate (BUD/FORM) 640/18 μg/day. Outcomes of the present pilot study support triple therapy with BUD/GLY/FORM as efficacious in improving lung function parameters including inspiratory capacity, intimating the possible value of triple therapy as standard treatment for ACO.